40 Dalton Street,

Boston,

MA,

US,

ZIP: 02115

Phone: +1 617 455 4188

Advancing Engineered, Native & Bispecific TCRs to Effectively Treat Solid Tumors
Do you want to gain unrivalled industry knowledge to build a first-class TCR-based therapy with high efficacy and targeting power in solid tumors?

The industry-leading TCR-based Therapies for Solid Tumors Summit returns for its third year to provide the perfect opportunity join the exclusive TCR community in Boston and uncover key learnings cross-industry in TCR discovery and selection to successfully target tumor-specific cells.

With the first commercial TCR therapy having reached approval, now is the perfect time to explore methods to discover novel targets and boost cell fitness to maximize the unparalleled benefits of these therapies in solid tumors.

Featuring 25 top-tier speakers, the TCR-based Therapies for Solid Tumors Summit will provide you with all the know-how needed to harness the power of TCRs.

Tickets    https://go.evvnt.com/1029444-2?pid=1052
Brochure https://go.evvnt.com/1029444-3?pid=1052

Prices:
Drug Developer Pricing - Conference + 2 Workshops - On the Door USD 4197.00
Drug Developer Pricing - Conference + 1 Workshop - On the Door USD 3598.00
Drug Developer Pricing - Conference Only - On the Door USD 2999.00
Standard Pricing - Conference + 2 Workshops - On the Door USD 5097.00
Standard Pricing - Conference + 1 Workshop - On the Door USD 4348.00
Standard Pricing - Conference Only - On the Door USD 3599.00
Academic Pricing - Conference + 2 Workshops - On the Door USD 3697.00
Academic Pricing - Conference + 1 Workshop - On the Door USD 3148.00
Academic Pricing - Conference Only - On the Door USD 2599.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development

Adrian Rawcliffe CEO Adaptimmune, Helen Tayton-Martin CBO Adaptimmune, Karen Miller SVP, Pipeline Research Adaptimmune, Hugh Salter CSO Anocca, Piotr Pierog VP, Precision & Translational Medicine Affini-T Therapeutics, Reagan Jarvis CEO Anocca, Abhishek Srivastava VP, Cell Therapy Development Athenex, Dongxing Zha CTO, TCR Discovery & Engineering Alloy Therapeutics, Sungeun Kim Principal Scientist, Oncology Research Amgen, Cheng Liu Founder & CEO Eureka Therapeutics, Dan Macleod VP, Discovery ImmunoScape, Stefania Gobessi Director, Discovery Gadeta, Franco Marincola SVP, Global Head of Research Kite Pharma, Kathrin Davari Director Medigene, Parameswaran Hari SVP, Clinical Science Iovance Biotherapeutics, Aaron Vernon VP, Manufacturing TCR2 Therapeutics, Shannon Oda Assistant Professor Seattle Children’s Research Institute & University of Washington, Thomas Andresen CEO T-Cypher Bio, Andy Bader CSO Triumvira Immunologics, Cagan Gurer VP, Discovery TScan Therapeutics, Peggy Sotiropoulou CSO T-knife Therapeutics, Drew Deniger VP, Research & Development Ziopharm, Eduardo Davila Professor, Dept of Medicine University of Colorado Comprehensive Cancer Center, Garry Menzel President & CEO TCR2 Therapeutics, Marvin Gee VP, Target Discovery & Co-Founder, 3T Biosciences